- Home
- RNAZ vs DRMA Comparison
RNAZ vs DRMA Comparison
Compare RNAZ & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- DRMA
- Stock Information
- Founded
- RNAZ 2016
- DRMA 2014
- Country
- RNAZ United States
- DRMA United States
- Employees
- RNAZ N/A
- DRMA N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- RNAZ Health Care
- DRMA Health Care
- Exchange
- RNAZ Nasdaq
- DRMA Nasdaq
- Market Cap
- RNAZ 7.2M
- DRMA 6.1M
- IPO Year
- RNAZ 2021
- DRMA 2021
- Fundamental
- Price
- RNAZ $8.08
- DRMA $1.25
- Analyst Decision
- RNAZ Strong Buy
- DRMA Strong Buy
- Analyst Count
- RNAZ 1
- DRMA 1
- Target Price
- RNAZ $20.00
- DRMA $6.00
- AVG Volume (30 Days)
- RNAZ 4.3M
- DRMA 465.7K
- Earning Date
- RNAZ 03-31-2025
- DRMA 03-20-2025
- Dividend Yield
- RNAZ N/A
- DRMA N/A
- EPS Growth
- RNAZ N/A
- DRMA N/A
- EPS
- RNAZ N/A
- DRMA N/A
- Revenue
- RNAZ N/A
- DRMA N/A
- Revenue This Year
- RNAZ N/A
- DRMA N/A
- Revenue Next Year
- RNAZ N/A
- DRMA N/A
- P/E Ratio
- RNAZ N/A
- DRMA N/A
- Revenue Growth
- RNAZ N/A
- DRMA N/A
- 52 Week Low
- RNAZ $2.66
- DRMA $1.00
- 52 Week High
- RNAZ $66.33
- DRMA $7.62
- Technical
- Relative Strength Index (RSI)
- RNAZ 48.31
- DRMA 52.68
- Support Level
- RNAZ $10.02
- DRMA $1.00
- Resistance Level
- RNAZ $11.30
- DRMA $1.28
- Average True Range (ATR)
- RNAZ 1.97
- DRMA 0.09
- MACD
- RNAZ -0.18
- DRMA 0.01
- Stochastic Oscillator
- RNAZ 26.75
- DRMA 74.07
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.